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Abstract 
Background: Intermittent theta-burst stimulation priming (iTBS-P) can improve clinical outcome 
of patients with Major Depressive Disorder (MDD) who do not show early benefit from 10 Hz 
stimulation of left dorsolateral prefrontal cortex (DLPFC), also known as high-frequency left-
sided (HFL) stimulation.  The intensity and pulse number for iTBS-P needed to induce clinical 
benefit have not been systematically examined.   
 
Objective: To study the effect of intensity and pulse number on the clinical efficacy of iTBS-P.   
 
Methods: We conducted a retrospective review of 71 participants who received at least five 
sessions of HFL with limited clinical benefit and received iTBS-P augmentation for between 5-
25 sessions.  Intensity of iTBS-P priming stimuli ranged from 75-120% of motor threshold (MT) 
and pulse number ranged from 600-1800.  Associations among intensity, pulse number, and 
clinical outcome were analyzed using a mixed methods linear model with change in IDS-SR as 
the primary outcome variable, priming stimulation intensity (subthreshold or suprathreshold), 
pulse number (<1200 or >1200 pulses), and gender as fixed factors, and number of iTBS-P 
treatments and age as continuous covariates.   
 
Results: Subjects who received subthreshold intensity iTBS-P experienced greater reduction in 
depressive symptoms than those who received suprathreshold iTBS-P (p=0.011) with no effect 
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Conclusions: Subthreshold intensity iTBS-P was associated with greater clinical improvement 
than suprathreshold stimulation.  This finding is consistent with iTBS-P acting through 









   5
Introduction 
Repetitive Transcranial Magnetic Stimulation (rTMS) of the left dorsolateral prefrontal 
cortex (DLPFC) is an established non-invasive brain stimulation treatment for Major Depressive 
Disorder (MDD).  Both 10 Hz (high-frequency left, or HFL rTMS) and intermittent theta burst 
stimulation (iTBS) are thought to induce synaptic plasticity and long-term potentiation (LTP) 
[1].  These approaches yield response rates between 40-50% and remission rates of up to 30% 
[2–5], leaving room for improvement.  
Few studies have examined methods to improve rTMS efficacy for patients who do not 
respond to HFL rTMS or iTBS. Traditional attempts to optimize rTMS outcomes in research 
contexts have focused on adjusting treatment parameters by enhancing accuracy of targeting the 
left DLPFC [6–8], extending the number of pulses or treatment sessions [9,10], sequential 
bilateral (SBL rTMS) stimulation [11,12] or accelerated rTMS [13,14], putatively inducing 
neural plastic changes with each treatment [15].   
Priming offers a potential alternative augmentation strategy [16].  Compared to SBL 
rTMS or accelerated rTMS, priming stimulation is a well-tolerated approach [5] that enhances 
rTMS-induced neural plasticity with little additional time, burden, and cost. Based upon results 
of preclinical studies of the motor system, priming uses a brief stimulus that is thought to lack 
independent therapeutic effects, and renders the cortex more receptive to the effects of a 
subsequent conditioning protocol [17,18].   
Several different rTMS priming paradigms have been examined in clinical contexts.  
Fitzgerald et al. [19] first applied a priming approach to the treatment of depression over the 
right DLPFC.  They found subjects receiving a brief, subthreshold 6 Hz priming stimulation 
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for four weeks experienced greater improvement in Montgomery-Asberg Depression Rating 
Scale scores compared to those receiving LFR rTMS alone.  More recently, Lefaucheur et al. 
[20] applied subthreshold iTBS as a priming stimulus over the motor cortex prior to a HFL 
treatment protocol in patients with chronic pain.  Subjects who received iTBS priming (iTBS-P) 
prior to their pain protocol experienced more analgesia than those who received continuous 
theta-burst priming or no priming at all.  Our group first examined iTBS-P augmentation of HFL 
in 17 subjects with MDD, delivering 600 pulses of iTBS (2s duration, 8s intertrain interval at up 
to 120% MT) immediately before standard HFL rTMS [21].  We found that among patients who 
failed to achieve a 20% decrease in depressive symptoms after two weeks of HFL rTMS [21], 
those who switched to an iTBS-P paradigm showed significantly better treatment response than 
those who received HFL rTMS or SBL rTMS treatment for the remainder of their 30 treatment 
sessions. In the present study, we include data from these patients as well as an additional 54 
patients who have since received iTBS-P in our clinic. 
There are two mechanisms through which priming is hypothesized to occur: neuronal 
gating or homeostatic plasticity [18,22].  According to neuronal gating theory, the priming 
stimulus determines outcome of the conditioning protocol – whether long-term potentiation 
(LTP) or long-term depression (LTD) – by inducing an excitatory or inhibitory state in the post-
synaptic neurons [23].  If the priming stimulus induces an excitatory state in the postsynaptic 
neurons, it is believed to remove voltage-gated magnesium blocks on NMDA receptors, leading 
to greater calcium influx, and, accordingly, greater LTP in response to the conditioning stimulus. 
If the priming stimulus is inhibitory, however, the voltage gated channels are thought to remain 
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According to gating theory, one might anticipate a highly excitatory priming stimulus to be more 
effective at inducing LTP.  
Homeostatic plasticity has been proposed as an alternative priming mechanism [23,24].  
According to the Bienenstock-Cooper-Munro theorem [17], the threshold for LTP induction by a 
conditioning stimulus depends on the preceding level of activation of the postsynaptic neuron 
[23]. Therefore, a suprathreshold priming stimulus that activates postsynaptic neurons is thought 
to raise the threshold of activation required for subsequent conditioning stimulus to induce LTP. 
Conversely, a subthreshold priming stimulus that has temporarily lowered postsynaptic activity, 
lowers the threshold of activation required of a conditioning stimulus to induce LTP in the same 
postsynaptic neuron. According to this perspective, subthreshold iTBS priming may enhance the 
relative effect of a subsequent conditioning protocol (i.e. HFL rTMS) by lowering the threshold 
of LTP induction.  
The optimal parameters for iTBS-P for MDD have not been systematically studied. It is 
unclear whether treatment outcome is impacted by the intensity of the priming stimulus or the 
number of priming pulses delivered.  If iTBS-P efficacy is attributable simply to the addition of 
greater treatment time per day, as performed in an “accelerated” rTMS approach [13,14,25,26] -- 
whereby multiple independently therapeutic treatment protocols are administered in succession – 
we might anticipate priming stimuli with greater intensity and pulse number to be more 
efficacious.  If iTBS-P enhances efficacy through a true priming effect, it is unclear whether the 
gating or homeostatic plasticity models best explain outcomes.  If iTBS-P acts through gating, 
we would anticipate that subjects who received both iTBS and HFL rTMS at suprathreshold 
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homeostatic plasticity is responsible for iTBS-P’s effects, those receiving subthreshold should 
fare better than those receiving suprathreshold iTBS-P.  
In this study, we examined whether iTBS-P intensity or pulse number were associated 
with better clinical outcome in subjects who failed to show early benefit from HFL rTMS 
stimulation of left DLPFC.   
 
Material and Methods 
Study Design 
 This was a retrospective review of patients receiving measurement-based care (in which 
protocol changes are made according to improvement thresholds achieved on standardized 
assessments) in the UCLA TMS Research and Clinical Service, from November 2018 to January 
2021. Weekly self-ratings of depression severity were collected using standardized 
questionnaires (i.e. IDS-SR). Treatment approaches are routinely assessed at treatment 10 and 
20, with changes in treatment protocol made according to a predefined treatment algorithm. This 
study was approved by the UCLA IRB for use of retrospective, anonymized clinical data. 
 
Study Subjects 
All subjects had a primary diagnosis of non-psychotic MDD confirmed on the MINI 
International Diagnostic Interview (MINI) at intake assessment [27].  All subjects had failed at 
least three antidepressant medication trials of adequate dose and duration, one augmentation 
strategy, and one evidence-based psychotherapy before initiating rTMS.  Subjects were not 
offered rTMS if they had any history of cardiac pacemaker, cochlear implant, deep brain 
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disorder.  All subjects completed assessments using the Inventory of Depressive 
Symptomatology Self-Report (IDS-SR) at weekly intervals beginning at pre-treatment baseline 
until treatment 30 [28].  IDS-SR scores correlate highly with other self-rated measures of 
depression severity such as the Beck Depression Inventory (BDI-II) [29] and clinician-rated 
measures such as the Hamilton Rating Scale for Depression (HAMD-17) [30] and the MADRS 
[31].  Subjects continued to take any medications as directed by their outpatient psychiatrist and 
were instructed to avoid starting, stopping, or adjusting the dosage of psychotropic medications 
during the course of rTMS treatment. The majority of patients maintained constant medication 
regimens during the course of treatment, but detailed week-by-week dosing data on all study 
subjects were not available. We included data from patients who received at least eight iTBS-P 
sessions during their treatment course as previous work has established that 80% of the maximal 
clinical benefit of iTBS-P occurs after a minimum of eight sessions [21]. 
 
rTMS Treatment 
All rTMS treatments were delivered with either a MagPro X100 (Magventure, Farnum, 
Denmark), Magstim Horizon (Magstim, Whitland, UK), or Magstim Super Rapid
2
 (Magstim, 
Whitland, UK) device.  We determined the resting motor threshold (RMT) – defined as the 
minimum stimulus intensity necessary to elicit an overt motor response in the right abductor 
pollicis brevis for ≥ 50% of applied stimuli – for each subject before the first treatment.  Subjects 
received 30 rTMS treatment sessions beginning with HFL rTMS, consisting of 10 Hz stimulation 
(4-s trains, 26-s intertrain intervals, 75 trains and 3000 pulses total) lasting 37.5 minutes daily to 
L-DLPFC using the Beam F3 localization method [6].  We increased HFL rTMS intensity to 
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rTMS was delivered using a measurement-based care paradigm described previously 
[21,32] in which change in depression severity scores obtained after every five treatments were 
used to modify treatment parameters.  Feffer et al. [33] showed that patients who did not improve 
at least 20% by treatment 10 were very likely to be non-responders at the end of a six-week 
treatment course (negative predictive value [NPV] > 85%).  iTBS-P augmentation was offered as 
a treatment option typically after ten sessions of HFL rTMS if subjects showed <20% decrease in 
symptoms from baseline by treatment , or earlier if in the clinical judgment of the treating 
psychiatrist a patient might benefit from such a change.  Subjects treated during the initial 24 
months of the study period generally received 600 iTBS-P pulses per Huang et al. [34] at 
subthreshold (80-90% MT) intensity, titrated (if at all) over the first week after initiating iTBS-P, 
immediately before HFL rTMS.  Li et al. [35] subsequently found that up to 1800 pulses of iTBS 
delivered at 120% MT could be effective for MDD [35].  We also delivered higher iTBS pulse 
number (1200-1800) and suprathreshold intensities (110-120% MT) as tolerated, with intensity 
and pulse number titrated as tolerated over one week.  
 
Data analysis 
Data analyses were performed using SPSS, version 27 with two-tailed tests, and an alpha 
level of 0.05.  Response was defined as a ≥50% improvement in IDS-SR score from pretreatment 
baseline to final assessment. Remission was defined as a final IDS-SR score ≤13.  
The mean iTBS-P intensity and pulse number were calculated within subjects across all 
of their iTBS-P sessions.  Subjects were categorized as receiving “subthreshold” (<100% MT 
treatment intensity) or “suprathreshold” (>100% MT) priming stimulation based on their mean 
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>1200 pulses) based on the mean number of priming pulses they received over their treatment 
course.  Potential baseline group differences in age at first HFL rTMS treatment, baseline IDS-
SR score, and total number of iTBS-P sessions were tested with independent samples t-tests. 
Differences in gender, medications, and response and remission rates between groups were 
assessed with a chi-square analysis.    
We fit a linear mixed methods (LMM) model with IDS-SR score as the primary outcome 
variable with fixed effects of intensity, pulse number, and gender. Number of iTBS-P sessions 
and age at first rTMS treatment were entered as covariates. Multiple imputation (with a linear 
regression approach) was employed to generate missing IDS-SR scores for the LMM analysis. 
All other means and standard deviations were calculated using available data from the original 
(non-imputed) data set.  
We subsequently conducted a sensitivity analysis using the original (non-imputed) data 
set and a general linear model (GLM) entering pulse number, intensity, and gender as between-




 71 patients (age 45.4  16.4, range 17-72) received HFL rTMS and at least eight 
subsequent sessions of iTBS-P for MDD. All patients offered iTBS-P elected to proceed with 
this augmentation strategy. Four patients (6%) were offered iTBS-P before session 8 based on 
the clinical judgment of the treating psychiatrist.  Eight patients (11%) received between 8-9 
HFL rTMS sessions before iTBS-P augmentation. The remaining 59 (83%) received 10 or more 
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sample was 43.1  10.4. Subjects received a mean of 12.5  4.2 (range 5-22) HFL rTMS 
treatment sessions before receiving a mean of 16.5  4.7 (range 8-25) iTBS-P sessions during 
their treatment courses.  There was no statistically significant difference in final IDS-SR score 
between those who received <10 or ≥10 HFL sessions before receiving iTBS-P. IDS-SR data 
were missing for 12 of a total 497 possible follow-up data points (2.4%). The overall group mean 
percent improvement in IDS-SR score from baseline to treatment 30 was 31.8  23.7 (range -9.8 
to 91.4).  
iTBS-P was well-tolerated with no subjects discontinuing augmentation treatment. No 
patients were hospitalized, or experienced mania, attempted suicide, or seizures.  
Demographic and baseline characteristics of study subjects in each group (i.e., 
subthreshold versus suprathreshold) are detailed in Table 1.  A total of 27 subjects received 
subthreshold iTBS-P, while 44 received suprathreshold iTBS-P.  No baseline group differences 
were found in age at first rTMS treatment, gender, baseline total IDS-SR score, number of HFL 
rTMS or iTBS-P sessions received, comorbid diagnoses, or medications.  Subjects who received 
subthreshold iTBS-P showed greater symptom reduction than those receiving suprathreshold 
augmentation (Figure 1), while those with greater or lesser numbers of pulses showed similar 
outcomes (Figure 2). LMM analysis revealed a significant effect of stimulus intensity 
F(1,65)=8.41, p=0.005 on treatment 30 IDS-SR score, favoring subthreshold stimulation, but no 
other significant effects. Table 2 details parameter estimates gleaned from the LMM analysis. No 
group differences in response or remission were detected.  Consistent with the LMM, a GLM 
using the non-imputed data set revealed a significant effect of iTBS-P intensity on final IDS-SR 
score (F=9.044, df=1, p=0.004). No other factor (pulse number, age, gender, or number of iTBS-
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Discussion 
We found that subthreshold priming intensity was associated with superior reduction in 
treatment-30 IDS-SR scores in those receiving iTBS-P for MDD when compared to 
suprathreshold priming.  According to the BCM theorem [23], a subthreshold priming stimulus 
that activates postsynaptic neurons only weakly lowers the threshold of activation necessary for a 
subsequent conditioning stimulus to induce LTP. Our findings are consistent with this priming 
theory and the existing literature base suggesting rTMS priming effects occur through 
homeostatic mechanisms [17,18,36].   
There was no statistical association between pulse number and final IDS-SR score though 
patients in the subthreshold group were significantly more likely to have received lower pulse 
number. Response (33% v 18%) and remission (19% and 5%) did not differ statistically between 
subthreshold and suprathreshold iBTS-P, respectively, however, the overall response and 
remission rates were low in both groups. It is possible that a larger sample with greater power 
could have revealed a statistically significant between-group difference. Feffer et al. [37] found 
that patients showing less than 20% improvement by treatment 10 had an NPV of 85% for non-
response by treatment end. Since the patients analyzed in this study all failed to show >20% 
improvement by week 2, it is perhaps surprising that response and remission both exceeded 15% 
in the subthreshold group. These findings suggest that the addition of subthreshold iTBS-P at 
treatment 11 was sufficient to augment the rate of response and remission (numerically) in 
patients drawn from a population otherwise unlikely to have responded. Brief subthreshold 
iTBS-P (i.e., 600 pulses delivered at <90% MT) may augment HFL rTMS as well or even better 
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While SBL rTMS initially showed promise as an augmentation strategy [38], Fitzgerald 
et al. [16] subsequently found equivocal benefit with this strategy. A meta-analysis by Chen et al. 
[39] also showed that SBL rTMS conferred no marginal benefit in clinical outcome, tolerability, 
or acceptability above HFL or LFR rTMS [39], while lengthening treatment time.  Mutz et al. [5] 
found in their comparative meta-analysis of non-invasive and invasive brain stimulation 
techniques that priming rTMS possessed the greatest odds of response compared to sham (6.02, 
95% confidence interval [CI] 2.21 to 16.38) amongst all rTMS interventions, outstripping SBL 
rTMS (4.92, CI 2.93 to 8.25), LFR rTMS (3.65, CI 2.13 to 6.24) and HFL rTMS (3.17, CI 2.29 
to 4.37).  Priming TMS was second only to bitemporal ECT (8.91, 2.57 to 30.91) and high dose 
right unilateral ECT (7.27, 1.90 to 27.78) in summary odds of response.  Notably, priming TMS 
was the most acceptable of rTMS approaches.  Our recent retrospective analysis showed that 
those who did not experience early clinical response with HFL rTMS (defined as a >20% 
improvement from baseline depression by 10 treatments) experienced a significant improvement 
in final rate of clinical response with the addition of iTBS-P [21].  In contrast, those who 
switched to SBL rTMS did not show any statistically significant improvement beyond those who 
continued to receive HFL rTMS for the remainder of their 30 treatments.  Taken together these 
findings provide real-world evidence of the value of iTBS-P as an augmentation strategy, 
suggesting that brief (600-pulse) subthreshold iTBS-P is a practical augmentation strategy for 
those failing to respond to HFL rTMS treatment in a time- and cost-sensitive clinical setting.   
It is important to note that we calculated priming stimulus intensity based on a percentage 
of RMT, not active motor threshold (AMT).  While Fitzgerald et al. [19] used 90% RMT for 
their 6 Hz priming stimulus intensity, Lefaucheur et al. [20] used 80% of AMT for their iTBS-P 
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dosing intensity could further enhance the efficacy and tolerability of iTBS-P augmentation.  The 
relatively greater effectiveness of a subthreshold priming intensity is consistent with a 
homeostatic model of priming plasticity, whereby a weak priming stimulus, too weak to 
independently activate a population of postsynaptic neurons, renders them more responsive to a 
subsequent treatment protocol [18].  
Although there was no difference in response or remission rates between groups, the 
overall rate of remission and response in this sample was low and the analysis likely 
underpowered to detect such a difference. Study subjects were drawn from a highly treatment-
resistant population that had failed to show improvement with HFL rTMS before starting iTBS-
P. Whether a significant between-group difference in response or remission could be detected 
with a larger sample remains speculative.  
It is not known whether iTBS-P would have clinical efficacy for augmenting treatments 
other than HFL rTMS.  Fitzgerald et al. [19] used HFL rTMS to prime LFR rTMS of the right 
DLPFC in their original study of priming rTMS for MDD.  Lefaucheur used iTBS-P to augment 
10 Hz stimulation at M1 [20].  Huang et al. [34] found that iTBS induced a longer period (60-90 
min) of motor cortical facilitation (a measure of neural plasticity in the motor cortex) than HFL 
rTMS (30 min).  It is unknown whether iTBS-P could keep different cortical areas in a primed 
state for other targets such as the supplementary motor area or dorsomedial prefrontal cortex.  
Future studies should examine such augmentation approaches systematically.   
 
Limitations 
The findings of this study should be interpreted in the context of several limitations.  
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program rather than through a randomized controlled trial. The limitations of such a study design 
have been previously discussed and include the potential for selection bias and confounding 
effects [41]. The absence of patients in either group dropping out and inclusion of all subjects 
treated with iTBS-P lowers the potential contribution of sampling bias.  Additionally, use of self-
report questionnaires maximized accrual of data from all patients meeting inclusion criteria. 
Second, almost all subjects were receiving concomitant treatment with psychotropic medications 
during rTMS. Baseline differences in medications were not associated with outcome, but the 
presence of medications could have affected study results. Third, while the vast majority of 
subjects held medications constant, it is possible that uncontrolled factors such as medication 
changes could have affected outcome in some subjects. Because these patients were highly 
refractory to medication, however, it is unlikely that medication changes during the course of 
rTMS would be responsible for significant changes in symptoms. Finally, priming intensity and 
pulse number were not experimentally controlled for but instead were assigned based upon a 
clinical protocol. It is possible that uncontrolled factors in the clinical setting could have affects 
assignment of intensity and pulse number. Future prospective testing of intensity and pulse 
number in a randomized controlled trial is needed to confirm these results. 
 
Conclusions 
These results indicate that subthreshold priming was associated with clinical outcomes 
that were superior to those of suprathreshold priming in subjects who did not show early benefit 
from standard 10 Hz treatment. These findings provide evidence to support the use of 
subthreshold iTBS-P as an effective augmentation strategy. These results are consistent with the 
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benefits of subthreshold iTBS-P.  Furthermore, these findings are of clinical significance as they 
demonstrate a briefer, less intense (and consequently more tolerable) priming stimulus was 
associated with better clinical response than a longer, more intense alternative. Clinicians aiming 
to improve outcomes could consider initiating subthreshold iTBS-P in those showing limited 
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Table 1. Demographic and clinical characteristics of study sample (n=71). Baseline averages 
and analyses reported here were drawn from the original (non-imputed) data set. One of 44 (2%) 
treatment 30 IDS-SR scores was missing from the original data set. A significant effect of 
intensity on final score was found using both the linear mixed methods analysis (LMM) analysis 
of the imputed data set, and subsequent sensitivity analysis using a general linear model (GLM) 
and the original (non-imputed) data set. IDS-SR: Inventory of Depressive Symptomatology Self-
Report, iTBS-P: intermittent theta burst priming, MT: Motor Threshold, SSRIs: Selective 
Serotonin Reuptake Inhibitors, NDRIs: Norepinephrine-dopamine reuptake inhibitors, SNRIs: 
serotonin-norepinephrine reuptake inhibitors, NaSSAs: Noradrenergic and specific serotonergic 
antidepressant, TCAs: tricyclic antidepressants, MAOIS: monoamine oxidase inhibitors.   
 
 





Age at first treatment 48.319.2 42.914.4 n.s. 
Gender     
Female 12 (44%) 23 (52%) n.s. 
Male 15 (56%) 20 (45%) n.s. 
Transgender (F>M) 0 (0%) 1 (2%) n.s. 
Mean Baseline IDS-SR 
Score 
40.510.5 44.810.1 n.s. 
Mean Number of iTBS-
P sessions 
15.74.6 16.94.7 n.s. 
Mean Intensity (%MT) 





Mean Number of 
Priming Pulses 
774.7265.5 962.7412.3 p=0.022 
600-1200 22 (81.4%) 26 (59.1%)  
1200-1800 5 (18.5%) 18 (40.9%)  
Comorbid Psychiatric 
Diagnoses 
   
Anxiety Disorder 14 (22%) 15 (34%) n.s. 
Posttraumatic Stress 
Disorder 
3 (11%) 6 (14%) n.s. 
Obsessive Compulsive 
Disorder 
0 (0%) 1 (23%) n.s. 
Eating Disorder 1 (4%) 2 (5%) n.s. 
Substance use Disorder 2 (7%) 1 (2%) n.s. 
Personality Disorder 0 (0%) 3 (7%) n.s. 
ADHD 2 (7%) 5 (11%) n.s. 
Concurrent Daily 
Medications  
  n.s. 
SSRIs 13 (48%) 17 (39%) n.s. 
SNRIs 5 (19%) 9 (20%) n.s. 
Atypical Antidepressants 
(NDRIs, NaSSAs) 
6 (22%) 16 (36%) n.s. 
Atypical Antipsychotics 10 (37%) 21 (48%) n.s. 
Mood 
Stabilizers/Antiepileptics 
9 (33%) 15 (34%) n.s. 
Stimulants 3 (11%) 12 (27%) n.s. 
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Non-benzodiazepine 
anxiolytics 
1 (4%) 3 (7%) n.s. 
TCAs 2 (7%) 1 (2%) n.s. 
MAOIs 1 (4%) 0 (0%) n.s. 
Alpha agonist 0 (0%) 3 (7%) n.s. 
Treatment 30 IDS-SR 24.611.2 32.613.1 p=0.011* 
Response 9 (33%) 8 (18%) p=0.253 
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Figure 1. Change in Absolute IDS-SR score by iTBS-P intensity (n=71). The original (not 
imputed) data set was used to generate this figure. Twelve data points of a possible 497 were 
missing (2.4%). Error bars show standard error of the mean. IDS-SR = Inventory of Depressive 
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Figure 2. Change in Absolute IDS-SR score by iTBS-P pulse number (n=71). The original 
(not imputed) data set was used to generate this figure. Twelve data points of a possible 497 were 
missing (2.4%). Error bars show standard error of the mean. IDS-SR = Inventory of Depressive 
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Table 2. Parameter table. 
 
 b SEb 95% CI 
Pulse Number 1.59 2.36 -3.12, 6.30 
Intensity  -6.60 2.38 -11.35, -1.84 
Gender 5.95 9.59 -13.20, 25.12 
Number of iTBS-P treatments  -0.25 0.25 -0.74, 0.24 










 Subthreshold iTBS priming (iTBS-P) of standard rTMS treatment improved MDD 
outcomes compared to suprathreshold iTBS-P 
 Priming pulse number (i.e. 600 pulses versus 1200 or more pulses) did not influence 
clinical response 
 Brief, subthreshold iTBS-P may be an efficient, tolerable, and effective way to augment 
outcomes from standard rTMS for MDD 
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